Protara Therapeutics Inc (TARA) concluded trading on Thursday at a closing price of $3.90, with 0.45 million shares of worth about $1.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 117.88% during that period and on April 17, 2025 the price saw a loss of about -2.50%. Currently the company’s common shares owned by public are about 35.04M shares, out of which, 32.88M shares are available for trading.
Stock saw a price change of 4.00% in past 5 days and over the past one month there was a price change of -17.20%. Year-to-date (YTD), TARA shares are showing a performance of -26.14% which increased to 36.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.60 but also hit the highest price of $10.48 during that period. The average intraday trading volume for Protara Therapeutics Inc shares is 269.50K. The stock is currently trading -6.90% below its 20-day simple moving average (SMA20), while that difference is down -4.43% for SMA50 and it goes to 18.90% higher than SMA200.
Protara Therapeutics Inc (NASDAQ: TARA) currently have 35.04M outstanding shares and institutions hold larger chunk of about 79.44% of that.
The stock has a current market capitalization of $143.39M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$2.40 in the same period. It has Quick Ratio of 15.71 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TARA, volatility over the week remained 7.05% while standing at 8.18% over the month.
Stock’s fiscal year EPS is expected to rise by 22.27% while it is estimated to decrease by -22.69% in next year. EPS is likely to shrink at an annualized rate of 2.40% for next 5-years, compared to annual growth of 55.31% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on April 16, 2025 offering a Sector outperform rating for the stock and assigned a target price of $12 to it. On July 10, 2023, Guggenheim Resumed their recommendations, while on June 04, 2021, H.C. Wainwright Initiated their ratings for the stock with a price target of $40. Stock get an Outperform rating from Oppenheimer on February 17, 2021.
